FDA Extends Nexplanon Use
US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.
-
By
-
Kathryn Wighton
-
January 20, 2026
-
-
1
The FDA approved extending Nexplanon's use from three years to five years based on clinical trial data.
-
2
The approval was supported by a study involving 399 women, showing no pregnancies during years 4 and 5.
-
3
No new safety findings were reported, and adverse reactions were consistent with the initial three years of use.
-
4
A Risk Evaluation and Mitigation Strategy (REMS) will be implemented to ensure proper insertion and removal.
-
5
Nexplanon is effective for pregnancy prevention but does not protect against HIV or other sexually transmitted diseases.
